iBio, Inc. and GE Healthcare form new global alliance

iBio, Inc. and GE Healthcare form new global alliance
--Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture --Innovative approach offers potential to reduce costs, increase manufacturing flexibility

NEWARK, Del. and CHALFONT ST GILES, England, July 26, 2012  -- iBio, Inc. (nyse mkt:IBIO), and GE Healthcare, the healthcare business of GE GE +0.15% , announced today a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's innovative plant-based vaccine manufacturing platform, iBioLaunch(TM), with GE Healthcare's world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.